Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|March 1, 2006
- Pharmaceutical Executive-03-01-2006
- Volume 0
- Issue 0
South Africa
Author(s)Frederic Boucheseiche, Kirsten Craze
Sponsored and produced by Focus Reports.
Advertisement
Articles in this issue
over 20 years ago
Global Report: Chemicals Legislation in Europeover 20 years ago
Pharma's Next Top Model: Slimmer Business Modelsover 20 years ago
Market Research Roundtableover 20 years ago
Holding Their Breath: Inhaled Insulinover 20 years ago
Sales Management: Spending Under Scrutinyover 20 years ago
Genzyme: The Price of Successover 20 years ago
Invisible Prescribers: What You Do and Don't Know About NPs and PAsover 20 years ago
From the Editor: Fine Whinesover 20 years ago
Legal: Hey, Good Lookin': Sex Discrimination in Hiring Repsover 20 years ago
Thought Leader: Q&A with Hugo StephensonAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5